Contact Us
Drug Search Results
More Filters [+]

Daptomycin

Alternative Names: daptomycin, cubicin, dapzura rt
Latest Update: 2024-11-19
Latest Update Note: Clinical Trial Update

Product Description

Daptomycin is a cyclic lipopeptide antibiotic derived from the organism Streptomyces roseosporus. Daptomycin is used to treat various bacterial infections caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE). (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK470407/)

Mechanisms of Action: Cell Wall Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Venezuela | Vietnam

Approved Indications: Endocarditis | Bacteremia | Central Nervous System Bacterial Infections | Endocarditis, Bacterial | Endocarditis | Bacteremia | Central Nervous System Bacterial Infections | Endocarditis, Bacterial | Pneumonia, Bacterial | Pneumonia

Known Adverse Events: Endocarditis | Hypertension | Hypotension | Abdominal Pain | Chest Pain | Dizziness | Headache | Pain Unspecified | Insomnia | Pruritus | Bacteremia | Sepsis | Urinary Tract Infections | Laryngeal Edema | Dyspnea | Diarrhea | Edema

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Daptomycin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title

09/25/2024

News Article

 The Bone Cement Market is projected to grow by USD 523.1 Million from 2024-2028, with AI reshaping the landscape and rising trauma-related orthopedic disorders boosting growth - Technavio

05/03/2024

News Article

 Basilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024

04/26/2024

News Article

 Bruker Further Enhances Clinical Microbiology & Infection Diagnostics Portfolio at ESCMID Global 2024 Conference

04/04/2024

News Article

 Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indications

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions